News Focus
News Focus
icon url

DewDiligence

01/28/16 3:59 PM

#12000 RE: biotech_researcher #11999

ABT—The hit to net income (and EPS) is much more than 2%. ABT used to make a decent profit in Venezuela, but now they’re losing money there.

If ABT were concerned only with the near future, they would surely pull out of Venezuela; however, ABT thinks the economy will right itself in due course.

p.s. Roche simply excluded the loss in Venezuela from all non-GAAP numbers by calling it "an FX issue." ABT is more honest.